Semaglutide and tirzepatide are arguably the most effective tools we've ever seen for weight loss outside of a surgical suite, but they aren't magic overnight fixes. I tell my patients in Florida all the time: this is a slow burn. Knowing exactly how these results unfold month-by-month is the best way to keep you from making the two classic mistakes: getting frustrated and quitting too soon, or trying to rush the dose and ending up miserable with side effects. [1]
The logic behind GLP-1 dosing
Both of these medications use a titration schedule. We start you at a low, 'loading' dose and step up every four weeks or so. We do this for a reason—it keeps the nausea and GI issues manageable while your system gets used to the new signals. Because of this, the heavy-hitting appetite suppression and the biggest scale victories usually don't happen until you've cleared those early titration hurdles. [2]
The first month (Weeks 1–4)
Month one is all about getting your feet wet. The starting dose is intentionally small because we're looking for tolerance, not a transformation. Honestly, if you lose more than a few pounds here, consider it a bonus. Most of my patients experience: [3]
- A noticeable drop in appetite during the first week or two—you'll just stop finishing your plate.
- That constant 'food noise' starts to fade into the background—it's finally quiet in your head.
- Temporary digestive quirks, like mild nausea or feeling 'backed up' for a day or two after your shot.
- Around 2–5 lb total loss, usually a mix of water weight and eating less overall.
If the scale doesn't budge much in month one, please don't panic. We are still building the foundation. [1]
Months 2–3: Finding your groove
By the time we hit the second and third months, you're usually reaching what we call a therapeutic dose. The appetite suppression feels more ironclad and consistent. For most folks in my clinic, this is when the steady, week-over-week progress really kicks in.
- Losing about 1–2 lb a week once we've found your sweet spot maintenance dose.
- Crossing that 5–10% total body weight loss mark by the end of twelve weeks.
- Clothes fitting noticeably better, energy levels stabilizing, and better numbers on your blood sugar labs.
- Side effects usually calm down as your body stops fighting the medication.
Months 4–6: The sweet spot
This is where the real work happens. In the clinical trials, this four-to-six-month window is usually where the weight loss curve is at its steepest. You aren't just losing water now—you're changing your body composition.
- On semaglutide, we're seeing an average of 10–15% body weight gone by month six.
- Tirzepatide patients often see even more, hitting that 15–20% range by this point.
- Visual changes become undeniable—your face looks different, and you're likely down a couple of sizes.
- Clinical markers often improve drastically, typically in blood pressure, A1c, and cholesterol levels.
Life after the six-month mark
Weight loss will eventually slow down as your body hits a new set point—that's just physiology. The big trial numbers you hear about—15% for semaglutide and 20%+ for tirzepatide—were measured out to 68 and 72 weeks. (2025 NEJM head-to-head trial: tirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks) To stay successful long-term, you've got to focus on protein, lifting some weights, and getting decent sleep. The medication is the engine, but you're still the driver.
Why some results lag
- Rushing the titration too fast, which forces us to stop or back down because of side effects.
- Mindlessly snacking through the appetite suppression without realizing the calories are adding up.
- Low protein intake—this is a big one—which causes muscle loss and tanks your metabolism.
- Missing doses or being inconsistent; these GLP-1s really need that steady weekly rhythm.
The reality check
Look—expect a slow start in month one, some real momentum by month three, and the 'wow' results by month six. These medications reward the patient who stays the course. I tell everyone: treat the first three months as the setup, and the next three as the payoff.
Available across Florida
Reset My Vitality is a Florida-licensed telehealth practice. The treatments covered in this guide are available to patients statewide, with medication shipped directly to your door. Explore the program for your city:
- Weight Loss in Miami, FL
- Weight Loss in Miami Beach, FL
- Weight Loss in Fort Lauderdale, FL
- Weight Loss in West Palm Beach, FL
- Weight Loss in Boca Raton, FL
- Weight Loss in Orlando, FL
- Weight Loss in Tampa, FL
- Weight Loss in Jacksonville, FL
- Weight Loss in Naples, FL
Key Clinical Studies
A short, responsible summary of recent peer-reviewed research relevant to this topic. This is for education only, not medical advice.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
New England Journal of Medicine · 2021
Key finding: In a randomized controlled trial, participants on semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight at 68 weeks vs 2.4% on placebo, with 86% achieving at least 5% loss.
Why it matters: Establishes the efficacy of semaglutide for substantial, sustained weight loss when paired with lifestyle support.
View studyTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine · 2022
Key finding: Participants on tirzepatide 15 mg lost up to 20.9% of body weight at 72 weeks vs 3.1% on placebo, with 91% achieving at least 5% loss.
Why it matters: Shows the strong average results possible with the dual GLP-1/GIP agonist tirzepatide for eligible patients.
View studyTwo-year effects of semaglutide in adults with overweight or obesity (STEP 5)
Nature Medicine · 2022
Key finding: A 104-week trial found mean weight loss of 15.2% with semaglutide vs 2.6% with placebo, with weight loss largely maintained over two years on treatment.
Why it matters: Demonstrates long-term durability of GLP-1 weight loss when therapy is continued under clinical supervision.
View studyScientific References
Peer-reviewed studies and reviews cited in this article.
- [1]Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. View study
- [2]Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. View study
- [3]Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. View study
